Cole G Bradley 4

What Happened Cole G Bradley, a director of Castle Biosciences, was granted 11,766 restricted stock units (RSUs) on May 28, 2026. The grant is reported as a derivative award (transaction code A) at $0.00 per RSU (11,766 RSUs @ $0.00 — reported value $0). This is an equity award, not an open-market purchase or sale.

Key Details

• Transaction date: May 28, 2026; Form 4 filed June 1, 2026 (filed within the required reporting window).
• Grant: 11,766 RSUs; price/consideration reported: $0.00 (derivative award).
• Shares owned after transaction: not specified in this filing.
• Footnote F1: Each RSU represents the right to receive one share of common stock upon vesting.
• Footnote F2 (vesting): RSUs vest in full on the earlier of (a) the one-year anniversary (May 28, 2027) or (b) the day immediately preceding the next Annual Meeting of Stockholders following the grant.
• Transaction type: Award/Grant (A). No 10b5-1 plan, tax-withholding, or late-filing flags are indicated in this filing.

Context RSUs are a deferred-compensation award that convert into shares only upon vesting; they do not represent immediately tradable shares. Because this is a grant (not a buy or sell), it should be viewed as compensation/retention-related rather than a direct signal of the director buying or selling company stock. The eventual value realized will depend on Castle Biosciences’ stock price at vesting.